Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was ...
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
Pfizer Investigational Site, São Paulo, SP, Brazil
Pfizer Investigational Site, Simferopol, Ukraine
AltaMed Health Services Corporation, Los Angeles, California, United States
Synergy Hematology-Oncology Associates, Los Angeles, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Usc La Nichd Crs, Los Angeles, California, United States
Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.